Customer contract revenue of Innovent Biologics 2019-2022
In 2022, the Chinese pharmaceutical firm Innovent Biologics Inc. received revenue of 4.56 billion yuan from customer contracts, a 6.8 percent increase from the previous year. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.